Total words: 2195 | 2-word phrases: 566 | 3-word phrases: 611 | 4-word phrases: 636
| Title | Try to keep the title under 60 characters (32 characters) Magnus Med Club LLC | Ohio, USA |
| Description | Try to keep the meta description between 50 - 160 characters (0 characters) |
| Keywords | Meta keywords are not recommended anymore (0 characters) Magnus med club, magnus med club llc, magnus med, open access publisher, magnus med club journals, magnus medical journals, magnus clinical journals, mmc |
| H1 | No H1 tag on the page (0 characters) |
| # | Keyword | H1 | Title | Des | Volume | Position | Suggest | Frequency | Density |
|---|---|---|---|---|---|---|---|---|---|
| 1 | of | 28 | 7.33% | ||||||
| 2 | the | 23 | 6.02% | ||||||
| 3 | to | 19 | 4.97% | ||||||
| 4 | and | 16 | 4.19% | ||||||
| 5 | fulltext | 15 | 3.93% | ||||||
| 6 | 15 | 3.93% | |||||||
| 7 | in | 12 | 3.14% | ||||||
| 8 | article | 11 | 2.88% | ||||||
| 9 | research | 11 | 2.88% | ||||||
| 10 | cancer | 9 | 2.36% |
| # | URL | Whois | Check |
|---|---|---|---|
| 1 | https://www.facebook.com | Whois | facebook.com |
| 2 | https://twitter.com/MagnusMedClub | Whois | twitter.com |
| 3 | https://www.oncogen.org/ | Whois | oncogen.org |
| 4 | https://jneuro.org/ | Whois | jneuro.org |
| 5 | https://www.jsurgery.org/ | Whois | jsurgery.org |
| 6 | https://www.jmedicalres.org/ | Whois | jmedicalres.org |
| 7 | https://www.jcardiac.com/ | Whois | jcardiac.com |
| 8 | https://www.jmaterialscience.com/ | Whois | jmaterialscience.com |
| 9 | https://www.jdentistry.com/ | Whois | jdentistry.com |
| 10 | https://www.traditionalmedicines.org/ | Whois | traditionalmedicines.org |
| 11 | https://www.jnanoparticle.com/ | Whois | jnanoparticle.com |
| 12 | https://www.jcases.org/ | Whois | jcases.org |
| 13 | https://www.oncogen.org/full-text/crispr-cas9-based-editing-of-cdk4-p107-and-tgf-1-in-human-breast-and-lung-cancer-cells | Whois | oncogen.org |
| 14 | https://www.oncogen.org/full-text/crispr-cas9-based-editing-of-cdk4-p107-and-tgf-1-in-human-breast-and-lung-cancer-cells | Whois | oncogen.org |
| 15 | https://www.oncogen.org/full-text/crispr-cas9-based-editing-of-cdk4-p107-and-tgf-1-in-human-breast-and-lung-cancer-cells | Whois | oncogen.org |
| 16 | https://www.oncogen.org/full-text/palliative-systemic-treatment-of-advanced-merkel-cell-carcinoma-in-the-pre-immunotherapy-era-a-retrospective-single-center-analysis-of-patients-with-an-orphan-neuroendocrine-malignancy | Whois | oncogen.org |
| 17 | https://www.oncogen.org/full-text/palliative-systemic-treatment-of-advanced-merkel-cell-carcinoma-in-the-pre-immunotherapy-era-a-retrospective-single-center-analysis-of-patients-with-an-orphan-neuroendocrine-malignancy | Whois | oncogen.org |
| 18 | https://www.oncogen.org/full-text/palliative-systemic-treatment-of-advanced-merkel-cell-carcinoma-in-the-pre-immunotherapy-era-a-retrospective-single-center-analysis-of-patients-with-an-orphan-neuroendocrine-malignancy | Whois | oncogen.org |
| 19 | https://www.oncogen.org/full-text/the-suppression-of-prolactin-is-required-for-the-treatment-of-advanced-prostate-cancer | Whois | oncogen.org |
| 20 | https://www.oncogen.org/full-text/the-suppression-of-prolactin-is-required-for-the-treatment-of-advanced-prostate-cancer | Whois | oncogen.org |
| 21 | https://www.oncogen.org/full-text/the-suppression-of-prolactin-is-required-for-the-treatment-of-advanced-prostate-cancer | Whois | oncogen.org |
| 22 | https://www.oncogen.org/full-text/post-translational-modifications-ptms-from-a-cancer-perspective-an-overview | Whois | oncogen.org |
| 23 | https://www.oncogen.org/full-text/post-translational-modifications-ptms-from-a-cancer-perspective-an-overview | Whois | oncogen.org |
| 24 | https://www.oncogen.org/full-text/post-translational-modifications-ptms-from-a-cancer-perspective-an-overview | Whois | oncogen.org |
| 25 | https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma | Whois | oncogen.org |
| 26 | https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma | Whois | oncogen.org |
| 27 | https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma | Whois | oncogen.org |
| 28 | https://www.oncogen.org/full-text/single-subject-studies-in-prostate-cancer-how-graphing-psa-test-results-and-testosterone-levels-using-process-behavior-and-celeration-charts-can-provide-insight-and-guide-clinical-decisions | Whois | oncogen.org |
| 29 | https://www.oncogen.org/full-text/single-subject-studies-in-prostate-cancer-how-graphing-psa-test-results-and-testosterone-levels-using-process-behavior-and-celeration-charts-can-provide-insight-and-guide-clinical-decisions | Whois | oncogen.org |
| 30 | https://www.oncogen.org/full-text/single-subject-studies-in-prostate-cancer-how-graphing-psa-test-results-and-testosterone-levels-using-process-behavior-and-celeration-charts-can-provide-insight-and-guide-clinical-decisions | Whois | oncogen.org |
| 31 | https://www.oncogen.org/full-text/a-clinical-study-of-biomarkers-to-predict-the-efficacy-of-cancer-immunotherapy-with-subcutaneous-low-dose-il-2-or-with-immune-checkpoint-inhibitors | Whois | oncogen.org |
| 32 | https://www.oncogen.org/full-text/a-clinical-study-of-biomarkers-to-predict-the-efficacy-of-cancer-immunotherapy-with-subcutaneous-low-dose-il-2-or-with-immune-checkpoint-inhibitors | Whois | oncogen.org |
| 33 | https://www.oncogen.org/full-text/a-clinical-study-of-biomarkers-to-predict-the-efficacy-of-cancer-immunotherapy-with-subcutaneous-low-dose-il-2-or-with-immune-checkpoint-inhibitors | Whois | oncogen.org |
| 34 | https://www.oncogen.org/full-text/tumor-infiltrating-lymphocytes-expression-in-stage-iiic-iv-of-high-grade-serous-ovarian-cancer-variation-with-neoadjuvant-chemotherapy-and-prognostic-value | Whois | oncogen.org |
| 35 | https://www.oncogen.org/full-text/tumor-infiltrating-lymphocytes-expression-in-stage-iiic-iv-of-high-grade-serous-ovarian-cancer-variation-with-neoadjuvant-chemotherapy-and-prognostic-value | Whois | oncogen.org |
| 36 | https://www.oncogen.org/full-text/tumor-infiltrating-lymphocytes-expression-in-stage-iiic-iv-of-high-grade-serous-ovarian-cancer-variation-with-neoadjuvant-chemotherapy-and-prognostic-value | Whois | oncogen.org |
| 37 | https://www.oncogen.org/full-text/triple-hormonal-blockade-adt3-a-patient-s-perspective | Whois | oncogen.org |
| 38 | https://www.oncogen.org/full-text/triple-hormonal-blockade-adt3-a-patient-s-perspective | Whois | oncogen.org |
| 39 | https://www.oncogen.org/full-text/triple-hormonal-blockade-adt3-a-patient-s-perspective | Whois | oncogen.org |
| 40 | https://www.oncogen.org/full-text/removal-of-carcinogenic-arsenic-from-drinking-water-by-the-application-of-ion-exchange-resins | Whois | oncogen.org |
| 41 | https://www.oncogen.org/full-text/removal-of-carcinogenic-arsenic-from-drinking-water-by-the-application-of-ion-exchange-resins | Whois | oncogen.org |
| 42 | https://www.oncogen.org/full-text/removal-of-carcinogenic-arsenic-from-drinking-water-by-the-application-of-ion-exchange-resins | Whois | oncogen.org |
| 43 | https://www.oncogen.org/full-text/breast-metachronous-carcinoma-and-sarcoma-in-a-young-patient-leading-to-the-diagnosis-of-li-fraumeni-syndrome | Whois | oncogen.org |
| 44 | https://www.oncogen.org/full-text/breast-metachronous-carcinoma-and-sarcoma-in-a-young-patient-leading-to-the-diagnosis-of-li-fraumeni-syndrome | Whois | oncogen.org |
| 45 | https://www.oncogen.org/full-text/breast-metachronous-carcinoma-and-sarcoma-in-a-young-patient-leading-to-the-diagnosis-of-li-fraumeni-syndrome | Whois | oncogen.org |
| 46 | https://www.oncogen.org/full-text/hearing-loss-tinnitus-and-pineal-germinoma-parinaud-dorsal-midbrain-syndrome-revisited | Whois | oncogen.org |
| 47 | https://www.oncogen.org/full-text/hearing-loss-tinnitus-and-pineal-germinoma-parinaud-dorsal-midbrain-syndrome-revisited | Whois | oncogen.org |
| 48 | https://www.oncogen.org/full-text/hearing-loss-tinnitus-and-pineal-germinoma-parinaud-dorsal-midbrain-syndrome-revisited | Whois | oncogen.org |
| 49 | https://www.oncogen.org/full-text/chromatographic-fractionation-of-an-ethanolic-extract-of-peels-from-ipomoea-batatas-lam-for-improved-anticancer-activity | Whois | oncogen.org |
| 50 | https://www.oncogen.org/full-text/chromatographic-fractionation-of-an-ethanolic-extract-of-peels-from-ipomoea-batatas-lam-for-improved-anticancer-activity | Whois | oncogen.org |
| 51 | https://www.oncogen.org/full-text/chromatographic-fractionation-of-an-ethanolic-extract-of-peels-from-ipomoea-batatas-lam-for-improved-anticancer-activity | Whois | oncogen.org |
| 52 | https://www.oncogen.org/full-text/primary-renal-lymphoma-a-case-report | Whois | oncogen.org |
| 53 | https://www.oncogen.org/full-text/primary-renal-lymphoma-a-case-report | Whois | oncogen.org |
| 54 | https://www.oncogen.org/full-text/primary-renal-lymphoma-a-case-report | Whois | oncogen.org |
| 55 | https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma | Whois | oncogen.org |
| 56 | https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma | Whois | oncogen.org |
| 57 | https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma | Whois | oncogen.org |
| 58 | https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma | Whois | oncogen.org |
| 59 | https://www.oncogen.org/full-text/post-translational-modifications-ptms-from-a-cancer-perspective-an-overview | Whois | oncogen.org |
| 60 | https://www.oncogen.org/full-text/the-suppression-of-prolactin-is-required-for-the-treatment-of-advanced-prostate-cancer | Whois | oncogen.org |
| 61 | https://www.oncogen.org/full-text/palliative-systemic-treatment-of-advanced-merkel-cell-carcinoma-in-the-pre-immunotherapy-era-a-retrospective-single-center-analysis-of-patients-with-an-orphan-neuroendocrine-malignancy | Whois | oncogen.org |
| 62 | https://www.oncogen.org/full-text/crispr-cas9-based-editing-of-cdk4-p107-and-tgf-1-in-human-breast-and-lung-cancer-cells | Whois | oncogen.org |
| 63 | https://twitter.com/MagnusMedClub?ref_src=twsrc%5Etfw | Whois | twitter.com |